Glen Eagle Advisors’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.68K | Hold |
160
| – | – | ﹤0.01% | 814 |
|
|
2025
Q1 | $2.46K | Hold |
160
| – | – | ﹤0.01% | 823 |
|
|
2024
Q4 | $3.53K | Hold |
160
| – | – | ﹤0.01% | 796 |
|
|
2024
Q3 | $2.88K | Hold |
160
| – | – | ﹤0.01% | 853 |
|
|
2024
Q2 | $2.6K | Hold |
160
| – | – | ﹤0.01% | 863 |
|
|
2024
Q1 | $2.26K | Hold |
160
| – | – | ﹤0.01% | 892 |
|
|
2023
Q4 | $1.67K | Hold |
160
| – | – | ﹤0.01% | 883 |
|
|
2023
Q3 | $1.63K | Hold |
160
| – | – | ﹤0.01% | 885 |
|
|
2023
Q2 | $1.21K | Hold |
160
| – | – | ﹤0.01% | 940 |
|
|
2023
Q1 | $1.42K | Hold |
160
| – | – | ﹤0.01% | 909 |
|
|
2022
Q4 | $1.46K | Hold |
160
| – | – | ﹤0.01% | 951 |
|
|
2022
Q3 | $1.29K | Buy |
+160
| New | +$1.29K | ﹤0.01% | 940 |
|
|
2021
Q1 | – | Sell |
-350
| Closed | -$3.38K | – | 1025 |
|
|
2020
Q4 | $3.38K | Hold |
350
| – | – | ﹤0.01% | 791 |
|
|
2020
Q3 | $3.15K | Hold |
350
| – | – | ﹤0.01% | 748 |
|
|
2020
Q2 | $4.32K | Buy |
350
+200
| +133% | +$2.47K | ﹤0.01% | 689 |
|
|
2020
Q1 | $1.35K | Buy |
+150
| New | +$1.35K | ﹤0.01% | 738 |
|
|
2019
Q1 | – | Sell |
-61
| Closed | -$941 | – | 755 |
|
|
2018
Q4 | $941 | Hold |
61
| – | – | ﹤0.01% | 676 |
|
|
2018
Q3 | $1.31K | Buy |
+61
| New | +$1.31K | ﹤0.01% | 657 |
|
|
2018
Q2 | – | Sell |
-100
| Closed | -$1.71K | – | 706 |
|
|
2018
Q1 | $1.71K | Hold |
100
| – | – | ﹤0.01% | 605 |
|
|
2017
Q4 | $1.9K | Sell |
100
-850
| -89% | -$16.1K | ﹤0.01% | 572 |
|
|
2017
Q3 | $16.7K | Sell |
950
-200
| -17% | -$3.52K | 0.02% | 361 |
|
|
2017
Q2 | $38.2K | Sell |
1,150
-5,674
| -83% | -$188K | 0.03% | 238 |
|
|
2017
Q1 | $223K | Buy |
6,824
+515
| +8% | +$16.8K | 0.19% | 115 |
|
|
2016
Q4 | $229K | Buy |
+6,309
| New | +$229K | 0.21% | 118 |
|